Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

PI3Kδ Inhibitor Idelalisib Inhibits AKT Signaling In Myelofibrosis Patients On Chronic JAK Inhibitor Therapy

Sarah A Meadows, Huong (Marie) Nguyen, M.D., Christophe Queva, PhD, Brian J. Lannutti, PhD, Adam Kashishian, Susie Jun, MD, PhD, Steven E. Coutre, MD, Roger Dansey, MD, Jason Gotlib, MD, MS

Blood (2013) 122 (21): 4065.

https://doi.org/10.1182/blood.V122.21.4065.4065

Published: 2013

Journal Articles

Interim Analysis Of Dose-Escalation Stage Of a Phase 1b Study Evaluating Safety and Pharmacology Of GS-9820, a Second-Generation, Selective, PI3Kd-Inhibitor in Recurrent Lymphoid Malignancies

Arnon P. Kater, MD PhD, Sanne H. Tonino, MD, PhD, Marie Jose Kersten, MD, PhD, Anton Hagenbeek, MD, PhD, Marjolein Spiering, Msc, Marinus H van Oers, MD PhD, Yan Xin, PhD, Srinivasan Ramanathan, PhD, Maria Aiello, MA, Susie Jun, MD, PhD

Blood (2013) 122 (21): 2881.

https://doi.org/10.1182/blood.V122.21.2881.2881

Published: 2013

Journal Articles

The Relative Bioavailability, Food Effect and Drug Interaction With Omeprazole Of Momelotinib Tablet Formulation

Yan Xin, PhD, Lixin Shao, MD MS, Wei Deng, PhD, Amanda Shaffer, Pharm D, Dimitrios Stefanidis, PhD, Jeffrey Hemenway, PhD, Xiaoming Li, PhD, Susie Jun, MD, PhD, Srini Ramanathan, PhD

Blood (2013) 122 (21): 5239.

https://doi.org/10.1182/blood.V122.21.5239.5239

Published: 2013

Journal Articles

Dose-Response Analyses Of Momelotinib (CYT387), a JAK1 and JAK2 Inhibitor, From a Phase I/II Study (CCL09101) In Treatment Of Myelofibrosis

Yan Xin, PhD, Lixin Shao, MD MS, Wei Deng, PhD, Demi Niforos, MS, Mark Kowalski, MD, PhD, Linda M Bavisotto, MD, Jun Kawashima, MD, Susie Jun, MD, PhD, Helen Collins, MD, Srinivasan Ramanathan, PhD

Blood (2013) 122 (21): 1590.

https://doi.org/10.1182/blood.V122.21.1590.1590

Published: 2013

Journal Articles

Pain and Health-Related Quality of Life (HRQoL) in Patients with Relapsed and Plateau-Phase (PP) Multiple Myeloma (MM) Treated with Denosumab

Karen C Chung, PharmD, MS, Arie Barlev, PharmD, MS, Yi Qian, PhD, Susie Jun, MD, PhD

Blood (2008) 112 (11): 2388.

https://doi.org/10.1182/blood.V112.11.2388.2388

Published: 2008

NARROW

PI3Kδ Inhibitor Idelalisib Inhibits AKT Signaling In Myelofibrosis Patients On Chronic JAK Inhibitor Therapy

Interim Analysis Of Dose-Escalation Stage Of a Phase 1b Study Evaluating Safety and Pharmacology Of GS-9820, a Second-Generation, Selective, PI3Kd-Inhibitor in Recurrent Lymphoid Malignancies

The Relative Bioavailability, Food Effect and Drug Interaction With Omeprazole Of Momelotinib Tablet Formulation

Dose-Response Analyses Of Momelotinib (CYT387), a JAK1 and JAK2 Inhibitor, From a Phase I/II Study (CCL09101) In Treatment Of Myelofibrosis

Pain and Health-Related Quality of Life (HRQoL) in Patients with Relapsed and Plateau-Phase (PP) Multiple Myeloma (MM) Treated with Denosumab

Email alerts

ASH Publications

American Society of Hematology

PI3Kδ Inhibitor Idelalisib Inhibits AKT Signaling In Myelofibrosis Patients On Chronic JAK Inhibitor Therapy

Interim Analysis Of Dose-Escalation Stage Of a Phase 1b Study Evaluating Safety and Pharmacology Of GS-9820, a Second-Generation, Selective, PI3Kd-Inhibitor in Recurrent Lymphoid Malignancies

The Relative Bioavailability, Food Effect and Drug Interaction With Omeprazole Of Momelotinib Tablet Formulation

Dose-Response Analyses Of Momelotinib (CYT387), a JAK1 and JAK2 Inhibitor, From a Phase I/II Study (CCL09101) In Treatment Of Myelofibrosis

Pain and Health-Related Quality of Life (HRQoL) in Patients with Relapsed and Plateau-Phase (PP) Multiple Myeloma (MM) Treated with Denosumab

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only